Credit Suisse Downgrades Pfizer (PFE)
Credit Suisse reported on Thursday that they have lowered their rating on biopharmaceutical company, Pfizer Inc.(PFE).
The firm has downgraded PFE from “Outperform” to “Neutral,” and has given the company a $29 price target. This price target suggests a 6% increase from the stock’s current price of $27.20.
Pfizer shares were down 19 cents, or -0.70% during Thursday morning trading. The stock has increased 29% in the past year.
The Bottom Line
Shares of Pfizer Inc.(PFE) have a 3.53% yield, based on Thursday morning’s price of $27.20.
Pfizer Inc.(PFE) is a “Recommended” dividend stock at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability